349 related articles for article (PubMed ID: 29297274)
21. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
22. Classification of drug-induced hERG potassium-channel block from electrocardiographic T-wave features using artificial neural networks.
Morettini M; Peroni C; Sbrollini A; Marcantoni I; Burattini L
Ann Noninvasive Electrocardiol; 2019 Nov; 24(6):e12679. PubMed ID: 31347753
[TBL] [Abstract][Full Text] [Related]
23. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
24. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
25. Sex-Specific Classification of Drug-Induced Torsade de Pointes Susceptibility Using Cardiac Simulations and Machine Learning.
Fogli Iseppe A; Ni H; Zhu S; Zhang X; Coppini R; Yang PC; Srivatsa U; Clancy CE; Edwards AG; Morotti S; Grandi E
Clin Pharmacol Ther; 2021 Aug; 110(2):380-391. PubMed ID: 33772748
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
[TBL] [Abstract][Full Text] [Related]
27. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
28. Contribution of haemodynamic side effects and associated autonomic reflexes to ventricular arrhythmias triggering by torsadogenic hERG blocking drugs.
Champéroux P; Fares R; Bastogne T; Richard S; Le Guennec JY; Thireau J
Br J Pharmacol; 2022 Sep; 179(18):4549-4562. PubMed ID: 35751378
[TBL] [Abstract][Full Text] [Related]
29. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
30. Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective.
Watt ED; Lee T; Feng SL; Kilfoil P; Ackley D; Keefer C; Wisialowski T; Jenkinson S
J Pharmacol Toxicol Methods; 2022; 118():107213. PubMed ID: 36084863
[TBL] [Abstract][Full Text] [Related]
31. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
Vicente J; Stockbridge N; Strauss DG
J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
[TBL] [Abstract][Full Text] [Related]
32. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
33. A 2015 focus on preventing drug-induced arrhythmias.
Bossu A; van der Heyden MA; de Boer TP; Vos MA
Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
[TBL] [Abstract][Full Text] [Related]
34. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
35. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
36. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
37. Drug-induced torsade de pointes: from molecular biology to bedside.
Tamargo J
Jpn J Pharmacol; 2000 May; 83(1):1-19. PubMed ID: 10887935
[TBL] [Abstract][Full Text] [Related]
38. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.
Patel N; Hatley O; Berg A; Romero K; Wisniowska B; Hanna D; Hermann D; Polak S
AAPS J; 2018 Mar; 20(3):47. PubMed ID: 29541956
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
40. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
